NCT03115996 is a Phase 1 clinical trial of REGN3918 in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals.

Who is sponsoring NCT03115996?

NCT03115996 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT03115996?

Interventions in NCT03115996: REGN3918, Placebo.

What condition does NCT03115996 study?

NCT03115996 studies Healthy Volunteers.

Is NCT03115996 still recruiting?

NCT03115996 is currently completed. Last updated 26 September 2018.

Last reviewed 2018-09-26 · How we verify

NCT03115996

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

Completed Phase 1 Last updated 26 September 2018

What this trial tests

Phase 1 trial testing REGN3918 in Healthy Volunteers in 56 participants. Completed in 31 August 2018.

Timeline

10 May 2017

Primary endpoint
31 August 2018

31 August 2018

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	basic science
Enrollment	56
Start date	10 May 2017
Primary completion	31 August 2018
Estimated completion	31 August 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

REGN3918 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

Adults 18 to 50, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses and a multiple dose regimen.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

New insights into the immune functions of complement.
Reis ES, Mastellos DC, Hajishengallis G, Lambris JD. · · 2019 · cited 357× · PMID 31048789 · DOI 10.1038/s41577-019-0168-x
The renaissance of complement therapeutics.
Ricklin D, Mastellos DC, Reis ES, Lambris JD. · · 2018 · cited 305× · PMID 29199277 · DOI 10.1038/nrneph.2017.156
Clinical promise of next-generation complement therapeutics.
Mastellos DC, Ricklin D, Lambris JD. · · 2019 · cited 255× · PMID 31324874 · DOI 10.1038/s41573-019-0031-6
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM, Marotta S, Ricci P, Marano L, et al · · 2019 · cited 155× · PMID 31258525 · DOI 10.3389/fimmu.2019.01157
Complement System in Cutaneous Squamous Cell Carcinoma.
Riihilä P, Nissinen L, Knuutila J, Rahmati Nezhad P, et al · · 2019 · cited 29× · PMID 31331124 · DOI 10.3390/ijms20143550
Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates.
Devalaraja-Narashimha K, Huang C, Cao M, Chen YP, et al · · 2022 · cited 15× · PMID 35709087 · DOI 10.1371/journal.pone.0269749
Targeting complement cascade: an alternative strategy for COVID-19.
Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, et al · · 2020 · cited 13× · PMID 33088671 · DOI 10.1007/s13205-020-02464-2
Association of complement pathways with COVID-19 severity and outcomes.
Devalaraja-Narashimha K, Ehmann PJ, Huang C, Ruan Q, et al · · 2023 · cited 9× · PMID 36494054 · DOI 10.1016/j.micinf.2022.105081

Verify or expand the search:

Other trials of REGN3918

Trials testing the same drug.

NCT04162470 — REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Toler · Phase 3 · terminated
NCT03946748 — Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) · Phase 2 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03115996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 26 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03115996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing